Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




A Rapid and Sensitive Lateral Flow Test for Diagnosis of Schistosomiasis

By LabMedica International staff writers
Posted on 01 Dec 2021
A novel lateral flow immunoassay enables the rapid and sensitive diagnosis of the urogenital form of schistosomiasis in both laboratory and field settings.

Schistosoma haematobium is the most common cause of urogenital schistosomiasis in humans, responsible for infection in approximately half of the estimated 200 million people with the disease throughout the world's tropical and subtropical regions. More...
Although there is no gold-standard recommended technique for detection of schistosomiasis, a widely used method for diagnosing infection involves microscopy-based detection of parasite eggs in urine, which can have poor sensitivity in areas of low transmission, limiting its diagnostic value in regions where the disease is present but uncommon.

Investigators at James Cook University (Cairns, Australia) screened the family of proteins secreted by the S. haematobium parasite to identify antibody biomarkers of schistosome infection, validate their diagnostic performance in samples from endemic populations, and evaluate their utility for use in point-of-care immunochromatographic tests (POC-ICTs) to diagnose urogenital schistosomiasis.

The initial screening study with serum and urine antibodies from endemic populations in Gabon, Tanzania, and Zimbabwe was carried out by collaborators at the University of Southern California (Los Angeles, USA), who fit nearly a thousand different S. haematobium antigens onto a microarray chip. Antigens that were found to be IgG-reactive were then evaluated by ELISA using both the same samples as well as additional samples from individuals residing in a low-endemicity settings (ie, Pemba and Unguja islands, Zanzibar, and Tanzania).

Results revealed that 208 antigens were the targets of significantly elevated IgG responses in serum, and 45 antigens were the targets of significantly elevated IgG responses in urine. Of the five proteins that were validated by ELISA, Sh-TSP-2 and MS3_01370 displayed the highest overall diagnostic performance in each biofluid and exceeded that of S. haematobium-soluble egg antigen in urine. When incorporated into separate POC-ICTs, Sh-TSP-2 showed absolute specificity and a sensitivity of 75% and MS3_01370 showed absolute specificity and a sensitivity of 89%. Thus, the Sh-TSP-2 and MS3_01370 antigens could be used as sensitive, specific, and field-deployable diagnostic biomarkers to support schistosomiasis control and elimination.

“This is a disease of poverty,” said first author Dr. Mark Pearson, research fellow at James Cook University. “Although there are effective drugs available to treat it, it becomes a serious health issue where contaminated drinking water and waterways lead to frequent reinfections. To interrupt the spread of the disease, a test needs to be sensitive enough to identify people with low-level infections, who can still pass the parasite on to others when they might not know they are infected themselves.”

The POC assay for schistosomiasis was described in the August 31, 2021, online edition of the journal The Lancet Microbe.

Related Links:
James Cook University
University of Southern California



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hand-Held Immunofluorescence Analyzer
WS-Si1500
New
Automated PCR System
OnePCR
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.